

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



Final Appraisal Recommendation

Advice No: 1112 – May 2012

**Atorvastatin (Lipitor®) 5 mg, 10 mg, 20 mg and 40 mg
chewable tablets**

Submission by Pfizer Ltd

Recommendation of the All Wales Medicines Strategy Group

Atorvastatin (Lipitor®) chewable tablets are recommended as an option for use within NHS Wales:

- as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the Fredrickson classification) when response to diet and other non-pharmacological measures is inadequate.
- to reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.
- for the prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.

Additional notes:

Atorvastatin chewable tablets (Lipitor®) for the above indication met the following criteria for eligibility for a limited submission:

- New formulation with a pro-rata or lower cost per treatment.
- Anticipated usage in NHS Wales is to be considered of minimal budgetary impact.
- Estimated small difference in cost compared to atorvastatin (Lipitor®) film coated tablets.

AWMSG is of the opinion that atorvastatin (Lipitor®) chewable tablets may be appropriate for prescribing by all prescribers within NHS Wales for the above indication.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available) and discussions at AWMSG.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in August 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation 1112: Atorvastatin (Lipitor®) 5 mg, 10 mg, 20 mg and 40 mg chewable tablets. May 2012.